使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Hello, and welcome to the Mesoblast financial results for the half year ended December 31, 2025. An announcement and presentation have been lodged with the ASX and are also available on the Home and Investor pages at www.mesoblast.com. (Operator Instructions)
您好,歡迎參加 Mesoblast 截至 2025 年 12 月 31 日止半年度的財務業績說明。公告與簡報已提交至澳洲證券交易所(ASX),亦可於 www.mesoblast.com 的首頁與投資人頁面查閱。(接線員指示)
As a reminder, this conference call is being recorded. Before we begin, let me remind you that during today's conference call, the company will be making forward-looking statements that represent the company's intentions, expectations or beliefs concerning future events.
提醒各位,本次電話會議將被錄音。在開始之前,提醒您在今天的電話會議中,公司將作出前瞻性陳述,該等陳述代表公司對未來事件的意圖、預期或信念。
These forward-looking statements are qualified by important factors set forth in today's announcement and the company's filings with the SEC, which could cause actual results to differ materially from those in such forward-looking statements.
這些前瞻性陳述受限於今日公告及公司向美國證券交易委員會(SEC)提交文件中所載的重要因素,該等因素可能導致實際結果與前瞻性陳述所述結果存在重大差異。
In addition, any forward-looking statements represent the company's views only at the date of this webcast and should not be relied upon as representing the company's views of any subsequent date. The company specifically disclaims any obligations to update such statements. With that, I would like to turn the call over to Paul Hughes.
此外,任何前瞻性陳述僅代表公司於本次網路直播當日的觀點,不應被依賴為代表公司於其後任何日期的觀點。公司明確聲明不承擔更新該等陳述的任何義務。接下來,我想把電話交給 Paul Hughes。
Paul Hughes - Head of Corporate Finance and Investor Relations
Paul Hughes - Head of Corporate Finance and Investor Relations
Thank you. Welcome, everyone, to the Mesoblast financial results call for the period ending December 31, 2025. My name is Paul Hughes. I'm Head of Corporate Finance and Investor Relations. In the room with me today is our CEO, Silviu Itescu; our CFO, Jim O'Brien; and our CCO, Marcelo Santoro.
謝謝。各位好,歡迎參加 Mesoblast 截至 2025 年 12 月 31 日止期間的財務業績電話會議。我叫 Paul Hughes。我是企業財務與投資人關係主管。今天與我同在會議室的有我們的執行長 Silviu Itescu、財務長 Jim O'Brien,以及商務長 Marcelo Santoro。
We have a presentation to run through highlighting the financial results and the operations for the period, and then we'll have some time for questions at the end. So now I'll hand over to Silviu to begin.
我們將進行一份簡報,重點說明本期的財務結果與營運情況,之後在結尾會留一些時間進行問答。現在我把時間交給 Silviu 開始。
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
Thank you, Paul. We could go to slide 4, please. This slide highlights the corporate priorities for 2026. We intend to continue to show strong growth in Ryoncil sales driven by market adoption. We will build a strong cash flow with judicious use of funds for operations and an optimal capital structure.
謝謝你,Paul。請切到第 4 頁投影片。本頁重點說明 2026 年的公司優先事項。我們計畫在市場採用的帶動下,持續展現 Ryoncil 銷售的強勁成長。我們將透過審慎運用營運資金與最佳化資本結構,建立強健的現金流。
Cultural transition is critical so that we can move to an efficient commercial organization. We will expand Ryoncil label indications and obtain approval -- seek to obtain approval for remestemcel-L products, our second-generation platform.
文化轉型至關重要,使我們能轉型為高效率的商業化組織。我們將擴大 Ryoncil 標籤適應症,並爭取 remestemcel-L 產品(我們的第二代平台)之核准——尋求取得核准。
Our manufacturing focus will seek to increase diversification, capacity and cost efficiency for our platforms, and we will continue to focus on appropriate commercial partnering backed by demonstrable value drivers, including FDA approvals, strong revenues and advanced clinical programs. Next slide, please. This year was marked by a very successful product launch.
我們的製造重點將著重於提升平台的多元化、產能與成本效率;同時,我們將持續聚焦於合適的商業合作夥伴關係,並以可證明的價值驅動因素作為支撐,包括 FDA 核准、強勁營收與先進的臨床計畫。請看下一頁投影片。今年以非常成功的產品上市為標誌。
We initially received FDA approval for Ryoncil in December 2024. Ryoncil is the first and only FDA-approved allogeneic mesenchymal stromal cell product. The product was launched in April of 2025 with revenues growing quarter-on-quarter. There is significant unmet need for continued uptake and increasing market adoption. And our net revenue from Ryoncil was USD49 million in the first half of FY26.
我們於 2024 年 12 月首次獲得 FDA 對 Ryoncil 的核准。Ryoncil 是第一個也是唯一一個獲 FDA 核准的同種異體間質基質細胞產品。該產品於 2025 年 4 月上市,營收逐季成長。在持續滲透與提升市場採用方面仍存在顯著未被滿足的需求。而我們在 26 財年上半年來自 Ryoncil 的淨營收為 4,900 萬美元。
Next slide, please. Thank you.
請看下一頁投影片。謝謝。
Paul Hughes - Head of Corporate Finance and Investor Relations
Paul Hughes - Head of Corporate Finance and Investor Relations
Thanks, Silviu. Jim will take us through the financial slides. Thanks, Jim.
謝謝你,Silviu。接下來由 Jim 帶我們看財務投影片。謝謝,Jim。
James O'Brien - Chief Financial Officer
James O'Brien - Chief Financial Officer
Thank you, Paul. Hi, everybody. I'd like to now review our first half fiscal 2026 operating results. And I should mention that all figures are in US dollars.
謝謝你,Paul。各位好。我現在想回顧 2026 財年上半年的營運結果。並且我需要說明,所有數字均以美元計。
Total revenues for the period were $51.3 million, driven by the successful launch of Ryoncil. Our net product revenues, as Silviu mentioned, were $49 million, and we had a gross margin of a strong 93%. Our R&D expenses for the period were $46.1 million compared to what we reported last year of $5.1 million.
本期總營收為 5,130 萬美元,主要由 Ryoncil 成功上市所帶動。如 Silviu 所提,我們的產品淨營收為 4,900 萬美元,毛利率高達 93%。本期研發費用為 4,610 萬美元,相較於去年我們報告的 510 萬美元。
Now last year's numbers were a bit skewed because we had a $23 million reversal of the inventory provision once we got approval of Ryoncil. Without that adjustment, the prior year number would have been about $18.1 million.
去年數字有些失真,因為在 Ryoncil 獲准後,我們回轉了 2,300 萬美元的存貨備抵。若不計該項調整,前一年度的數字約為 1,810 萬美元。
So -- I'm sorry, we would have grown about $18.1 million over the prior year. And again, the spending in the period really related to our adult GVHD trials, back pain, and also our LVAD program as well as getting ready for the BLA and some manufacturing work.
所以——抱歉,我們相較前一年度約增加了 1,810 萬美元。再次說明,本期支出主要與我們的成人 GVHD 試驗、背痛項目,以及 LVAD 計畫相關,並包含為 BLA 申請做準備及部分製造工作。
Our sales and general and administrative expenses were $28.5 million compared to $18 million in the prior year. And that increase really related to the sales and marketing effort that Marcelo and the sales team did in terms of driving sales growth. The loss during the period this year was $40.2 million compared to $48 million in the prior year period.
本期銷售、一般及行政費用為 2,850 萬美元,前一年度為 1,800 萬美元。該增加主要與 Marcelo 與銷售團隊為推動銷售成長所進行的銷售與行銷投入有關。本期虧損為 4,020 萬美元,前一年度同期為 4,800 萬美元。
Again, as I mentioned a few moments ago, that prior year loss was impacted by the $23 million worth of reversal on inventory. And -- but for not those items, we were down -- we were up about -- we were down on a net loss of about $30 million year-over-year. Just in terms of our operating spend and our cash flows for the first fiscal quarter -- first fiscal half of the year, excuse me, we were at $30.3 million.
再次如我稍早所提,前一年度的虧損受到 2,300 萬美元存貨回轉的影響。若不計該等項目,我們的淨虧損年對年約減少 3,000 萬美元。就本年度第一個會計季度——抱歉,是本年度上半年的營運支出與現金流而言,我們為 3,030 萬美元。
As we look to the second half of the year, we expect our operating cash flow usage to decline when compared to the first half of fiscal '26 based upon our projected cash receipts from revenues as well as maintaining disciplined cost control measures and efficiencies in the operation. And on the next slide, just to point out our profitability and growth pipeline from Ryoncil.
展望下半年,基於我們預估的營收現金收款,以及持續維持嚴謹的成本控管措施與營運效率,我們預期營運現金流使用量將較 26 財年上半年下降。下一頁投影片,我想指出 Ryoncil 帶來的獲利能力與成長管線。
As I mentioned, we had strong revenues for the period. Gross margin, excluding amortization expense would have been about $44.2 million. Our direct selling costs were $7.7 million. And again, we have strong operating performance that allows us to invest in our R&D programs and our life cycle extensions. And we do have a very robust pipeline, and we continue to invest in our manufacturing footprint as well as building inventory where needed and getting our second-generation products to market.
如我所提,本期營收表現強勁。毛利(不含攤銷費用)約為 4,420 萬美元。我們的直接銷售成本為 770 萬美元。同時,我們強勁的營運表現使我們得以投資於研發計畫與產品生命週期延伸。我們確實擁有非常強健的產品管線,並持續投資於製造佈局、在需要時建立存貨,以及推動第二代產品上市。
On page 9, next slide, please. We had $130 million worth of cash at the end of December of this year, which you can also note that the reduction in our net spend over the year, as I said, will decline over the second half of this year.
第 9 頁,請看下一頁投影片。截至今年 12 月底,我們持有 1.30 億美元現金;您也可以注意到,如我所說,我們的淨支出在今年下半年將會下降。
On December 30, 2025, we entered into a $125 million nondilutive credit line facility. The first tranche of which is $75 million was drawn at closing and enabled Mesoblast to replay in full its prior senior secured loan. We also partially repaid the subordinated royalty facility, which will continue to be reduced from ongoing revenue and will be fully repaid by the middle of 2026.
於 2025 年 12 月 30 日,我們簽訂了一項 1.25 億美元的非稀釋性信用額度融資。其中第一期 7,500 萬美元已於交割時提用,使 Mesoblast 得以全額償還先前的優先擔保貸款。我們亦部分償還了次順位權利金融資,該融資將隨持續的營收而進一步降低,並將於 2026 年年中前全數償還。
The second tranche of $50 million is available to be drawn on our option through June of 2026. The new facility has a lower cost of capital for the company, freed up its major assets to provide flexibility for strategic partnerships and commercialization.
第二筆5,000萬美元的分期款可由我們自行選擇於2026年6月前動用。新的融資安排降低了公司資金成本,並釋放了公司的主要資產,以便在策略性合作夥伴關係與商業化方面提供更大的彈性。
In addition, the new facility can be repaid at any time without incurring early prepayment or make-whole fees. It does not include any exit fees and does not cover any of Mesoblast assets, which is a very strong point for the reason why we did this. This is terrific for the company.
此外,該新融資安排可於任何時間償還,且不會產生提前清償費或補償費(make-whole fee)。它不包含任何退出費用,且不涵蓋Mesoblast的任何資產,這也是我們之所以這麼做的一個非常強的理由。這對公司來說非常棒。
And we have no restrictions on doing additional unsecured debt or any licensing activities. We're very pleased with this line of credit and believe it will strengthen our balance sheet to support an exciting growth period for Mesoblast. On the next slide, looking ahead to the second half of 2026, we anticipate full year Ryoncil net revenues to range between $110 million and $120 million on a full year basis. With that, I'll turn the call back to Silviu for additional comments.
而且我們在進行額外的無擔保債務或任何授權活動方面沒有任何限制。我們對這條信用額度非常滿意,並相信它將強化我們的資產負債表,以支持Mesoblast令人振奮的成長期。看下一張投影片,展望2026年下半年,我們預期Ryoncil全年淨營收按全年基礎計算將介於1.10億至1.20億美元之間。接下來我把電話交回給Silviu做進一步評論。
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
Thanks, Jim. If we can go to slide 12, I'd like to bring Marcelo Santoro our Chief Commercial Officer, please.
謝謝,Jim。如果可以到第12張投影片,我想請我們的首席商務長Marcelo Santoro上來。
Marcelo Santoro - Chief Commercial Officer
Marcelo Santoro - Chief Commercial Officer
Thank you very much. Next slide, please. So good afternoon, good morning, everyone. We are extremely pleased with the performance of the launch to date, and I couldn't be proud of the work, the commitment, and the passion that our colleagues at Mesoblast demonstrate every single day towards these children.
非常感謝。請下一張投影片。各位下午好、早安。我們對目前為止的上市表現感到非常滿意,我也為Mesoblast同仁每天對這些孩子所展現的工作成果、投入與熱情感到無比自豪。
We have treated numerous patients since we launched and Ryoncil is having a transformational impact in the treatment of these children according to the feedback we received from treatment centers and treatment teams.
自上市以來我們已治療了許多患者,根據我們從治療中心與治療團隊收到的回饋,Ryoncil在這些孩子的治療上正帶來具變革性的影響。
In fact, we are on track to achieve 20% market share by the end of year one in the market. The commercial performance to date has been exceptional. This holds true not only against our initial expectations, but also when benchmarked against other successful rare disease launches. We have been laser-focused on building the infrastructure needed to ensure Ryoncil reaches its full potential. I am very happy to report that we have onboarded 49 treatment centers to date.
事實上,我們正按計畫在上市第一年年底前達成20%的市占率。迄今為止的商業表現非常出色。這不僅優於我們最初的預期,與其他成功的罕見疾病上市案例相比也同樣亮眼。我們一直高度聚焦於建立所需的基礎設施,以確保Ryoncil能充分發揮其潛力。我很高興向各位報告,截至目前我們已完成49個治療中心的導入。
In addition, Ryoncil is now listed on the formulary of 30 of those centers, a number that continues to grow steadily as more P&T committees review and approve its use. Formulary inclusion is critical, as you know, as it streamlines the adoption and use of Ryoncil when it's selected for a patient. Having these many formulary approvals in less than one-year demonstrates the outstanding value of the product and the tireless commitment of the team to build the appropriate infrastructure to expand utilization.
此外,Ryoncil目前已被其中30個中心納入處方集(formulary),且隨著更多藥事與治療(P&T)委員會審查並核准其使用,這個數字仍在穩定成長。如各位所知,納入處方集至關重要,因為當為某位患者選用Ryoncil時,這能簡化其採用與使用流程。在不到一年的時間內取得如此多的處方集核准,展現了產品的卓越價值,以及團隊不懈投入、建立適當基礎設施以擴大使用的承諾。
In addition, 13 hospitals have opted to use Optum Frontier, our specialty pharmacy partner, virtually eliminating their financial responsibilities with the product. On the payer side, we have also made exceptional progress.
另外,有13家醫院選擇使用Optum Frontier(我們的專科藥局合作夥伴),幾乎消除了他們在該產品上的財務責任。在支付方方面,我們也取得了卓越的進展。
Ryoncil is now covered by insurance plans, representing over 280 million lives across both commercial and government payers. Medicaid coverage is in place in all states and a specific J-Code for Ryoncil, J3402 went into effect on October 1, allowing for more efficient billing and reimbursement for both sites of care and payers, along with CMS published rates.
Ryoncil目前已獲保險計畫承保,涵蓋商業與政府支付方合計超過2.8億人。所有州的Medicaid承保均已到位,且Ryoncil的專屬J碼J3402已於10月1日生效,使照護機構與支付方能更有效率地進行帳單申報與給付,同時也有CMS公布的費率。
Commercial payer support has also been very strong. All major payers, including Aetna, Cigna, UnitedHealthcare, Anthem, Humana, and Prime Therapeutics covering all Blue Cross plans have issued favorable coverage policies for Ryoncil. Notably, these policies do not require step therapy, which simplifies patient access significantly.
商業支付方的支持也非常強勁。所有主要支付方,包括Aetna、Cigna、UnitedHealthcare、Anthem、Humana,以及涵蓋所有Blue Cross計畫的Prime Therapeutics,均已對Ryoncil發布有利的承保政策。值得注意的是,這些政策不要求階梯式治療(step therapy),大幅簡化了患者取得治療的流程。
All of this has occurred within the first six months post launch. Next slide, please. From a strategic priority standpoint, the Ryoncil team is 100% focused on three key strategic pillars. The first is to proactively identify and prioritize appropriate patients who may benefit from Ryoncil therapy. The second to reinforce our superior patient outcomes in first-line treatment right after steroids. And the third is to empower caregivers to demand Ryoncil for their children. We have been working with several advocacy groups and will soon launch a comprehensive campaign dedicated to supporting both caregivers and patients. With that, let me turn back to Paul.
上述所有進展都發生在上市後的前六個月內。請下一張投影片。從策略優先事項的角度來看,Ryoncil團隊100%聚焦於三大關鍵策略支柱。第一是主動辨識並優先排序可能受益於Ryoncil治療的合適患者。第二是在類固醇之後的第一線治療中,強化我們更優異的患者療效。第三是賦能照護者,讓他們為孩子主動要求使用Ryoncil。我們一直與多個倡議團體合作,並將很快推出一項全面性的活動,專注於支持照護者與患者。接下來我把時間交回給Paul。
Paul Hughes - Head of Corporate Finance and Investor Relations
Paul Hughes - Head of Corporate Finance and Investor Relations
Thanks, Marcelo. I'll hand over to Silviu, who's going to take us through the rest of the deck before we open it up to Q&A. Thanks.
謝謝,Marcelo。我把時間交給Silviu,他將在我們開放問答之前帶大家看完其餘投影片。謝謝。
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
Thank you. If we could move to slide 14. This slide summarizes our plans for label expansion of Ryoncil into adults. A pivotal study of Ryoncil as part of second-line treatment regimen in adults with severe steroid-refractory graft versus host disease is underway with our partners at the NIH-funded Bone Marrow Transplant Clinical Trials Network. The basis for this trial is that 50% of adults who have severe GVHD fail existing second-line treatment, including predominantly ruxolitinib.
謝謝。如果我們可以到第14張投影片。這張投影片總結了我們將Ryoncil適應症標籤擴展至成人的計畫。一項關鍵性研究正在進行中,評估Ryoncil作為重度、對類固醇無反應之移植物抗宿主病(GVHD)成人患者第二線治療方案的一部分;該研究與NIH資助的骨髓移植臨床試驗網絡合作進行。本試驗的依據在於:有50%的重度GVHD成人患者在現有第二線治療(主要包括ruxolitinib)下仍會治療失敗。
These patients who fail have a 25% abysmal survival at 100 days. We have previously used Ryoncil under expanded access in patients aged 12 and older, in many adults as well, 18 and older who have failed ruxolitinib or other second-line agents and use of our product in this patient population was associated with 76% survival at day 100, a remarkable result.
這些治療失敗的患者在第100天的存活率僅有25%,情況非常嚴峻。我們先前已在擴大使用(expanded access)下使用Ryoncil於12歲及以上患者,也包括許多18歲及以上的成人;這些患者曾對ruxolitinib或其他第二線藥物治療失敗,而在此族群中使用我們的產品與第100天76%的存活率相關,這是非常顯著的結果。
As a result of these results, the final protocol design for the registrational study in adults has been locked down and has been worked through with the FDA recently in a meeting with the FDA agency. We expect that following Central Institutional Review Board approval coming up in March, site initiation and patient enrollment will commence. Next slide, please.
基於上述結果,成人註冊性研究的最終方案設計已定案,並且近期已在與FDA的會議中完成討論。我們預期在3月即將取得中央機構審查委員會(Central IRB)核准後,將啟動各研究中心並開始收案。請下一張投影片。
Further extension strategy for Ryoncil is focused on various opportunities in pediatric and adult inflammatory diseases. The team is currently evaluating multiple indications to unlock value, including in the inflammatory bowel, neurodegenerative and respiratory conditions. Our portfolio will be prioritized to maximize shareholder return by utilizing either internal investment strategies versus external partnership initiatives.
Ryoncil的進一步延伸策略聚焦於兒科與成人發炎性疾病的多項機會。團隊目前正在評估多個適應症以釋放價值,包括發炎性腸道疾病、神經退化性疾病與呼吸系統疾病。我們將透過內部投資策略或外部合作夥伴計畫來優先排序產品組合,以最大化股東報酬。
Next slide, slide 16. Now I'll be updating you on our second-generation platform, rexlemestrocel-L currently being developed for discogenic chronic low back pain and chronic ischemic heart failure.
請下一張投影片,第16張。接下來我將向各位更新我們的第二代平台rexlemestrocel-L,目前正開發用於椎間盤性慢性下背痛與慢性缺血性心衰竭。
Slide 17, our Phase III chronic low back pain program, a first 404-patient randomized controlled Phase III trial has already completed, and that included about 40% of patients who are opioid dependent. We met with the FDA recently and received positive feedback on potential filing of a BLA based on achieving a clinically meaningful reduction in pain intensity at 12 months between the treatment arm and placebo arm.
第17張投影片,我們的第三期慢性下背痛計畫:第一項納入404名患者的隨機對照第三期試驗已完成,其中約40%的患者為阿片類藥物依賴者。我們近期與FDA會面,並就可能基於治療組相較安慰劑組在12個月時達到具臨床意義的疼痛強度降低而提交BLA,獲得正面回饋。
The robust result in opioid reduction from at least one adequate and well-controlled trial could be included according to our meeting with the agency as part of product labeling, which is a very, very, very important outcome. We, in fact, do already have an RMAT, Regenerative Medicine Advanced Therapy designation for rexlemestrocel-L as a potential opioid-sparing therapy in chronic lower back pain.
根據我們與主管機關的會議結果,至少一項充分且良好對照試驗所呈現的阿片類用量降低之強勁結果,可望納入產品標示中,這是一個非常、非常、非常重要的成果。事實上,我們已取得rexlemestrocel-L在慢性下背痛中作為潛在減少阿片類使用療法的RMAT(再生醫學先進療法)資格認定。
Next slide. The confirmatory Phase III trial is recruiting currently 300 patients across 40 sites in the US with a primary endpoint, 12-month reduction in pain. As I've mentioned on multiple occasions, FDA has confirmed that, that is an approvable endpoint. The enrollment of these 300 patients is expected to be completed in March or April. Data readout and BLA filing are expected in calendar year 2027.
下一張投影片。這項確認性第三期試驗目前正在招募,在美國40個試驗中心共納入300名病患,主要終點為12個月疼痛降低。如我多次提到,FDA已確認這是一個可獲核准的終點。預期這300名病患的收案將於3月或4月完成。資料讀出與BLA遞交預計在2027曆年進行。
We have, at the same time, undergoing commercial manufacturing in order to leverage our existing capacity and cost efficiencies. I will reinforce that there are many patients who are suffering from this terrible disease. Over 7 million patients across each of the US and EU5 are due to generative this disease, patients who are otherwise have run out of options other than surgery. This is a large unmet need for a potential blockbuster opportunity.
同時,我們也在進行商業化製造,以便運用我們既有的產能與成本效率。我要再次強調,有許多病患正飽受這種可怕疾病之苦。在美國與EU5各自都有超過700萬名病患受此疾病影響,這些病患除了手術之外往往已別無選擇。這是一項龐大的未被滿足醫療需求,具備成為潛在重磅產品的機會。
Next slide, slide 19. Now I'd like to update you on Revascor, our product based on our rexlemestrocel-L platform that is being developed for chronic heart failure with reduced ejection fraction and persistent inflammation in either patients with Class II/III heart failure or very end-stage heart failure patients who are being kept alive with a ventricular assist device in the left ventricle.
下一張投影片,第19張。現在我想向各位更新Revascor;這是我們基於rexlemestrocel-L平台的產品,正在開發用於射出分率降低且伴隨持續性發炎的慢性心衰竭,適用對象包括NYHA II/III級心衰竭病患,或是以左心室輔助裝置(LVAD)維持生命的極末期心衰竭病患。
We can go to Slide 20. LVAD implantation improves overall survival in these end-stage patients, and that's well established. However, the underlying causes of heart failure in these patients, notably inflammation, persists.
我們可以看第20張投影片。在這些末期病患中,植入LVAD可改善整體存活率,這點已被充分證實。然而,這些病患心衰竭的根本原因,尤其是發炎,仍然持續存在。
And whilst the left ventricle improving the left side -- the LVAD is improving on the left side of the heart, the right ventricular pump function remains vulnerable and continues to deteriorate. Therefore, progressive right heart failure continues to occur in up to 30% of patients and is the primary cause of multi-organ failure and death in this group of patients, mortality occurring within the first 12 months.
而且,雖然LVAD改善了心臟左側(左心室)的功能,但右心室的泵浦功能仍然脆弱並持續惡化。因此,進行性右心衰竭在多達30%的病患中仍會發生,且是此族群多重器官衰竭與死亡的主要原因,死亡多發生於前12個月內。
In addition, life-threatening major mucosal bleeding due to progressive right heart failure and portal hypertension occur in about 30% of patients and is the major morbidity in this group, the main cause of recurrent hospitalization. Next slide. Now we performed two randomized controlled studies in this patient population.
此外,由於進行性右心衰竭與門脈高壓所致、危及生命的重大黏膜出血約發生於30%的病患,是此族群的主要罹病負擔,也是反覆住院的主要原因。下一張投影片。我們在這個病患族群中進行了兩項隨機對照研究。
The more recent study was called LVAD Study II, and that randomized 159 patients in a 2:1 randomization to provide primary evidence of Revascor's efficacy in reducing major bleeding events. A second study, LVAD Study I, an earlier study, is a supportive study for LVAD II, randomized 30 patients in a 2:1 fashion and provided supportive evidence also of Revascor's efficacy in reducing major bleeding events.
較近期的研究稱為LVAD Study II,將159名病患以2:1比例隨機分派,提供Revascor在降低重大出血事件方面療效的主要證據。第二項研究LVAD Study I為較早期研究,作為LVAD II的支持性研究,將30名病患以2:1比例隨機分派,同樣提供Revascor降低重大出血事件療效的支持性證據。
Intramyocardial injections in both of these studies of either Revascor or control were performed at the time of LVAD implantation. Importantly, both trials, both randomized controlled trials showed the Revascor reduced cumulative incidence of major bleeding events, life-threatening GI bleeding, the trial's primary efficacy and safety endpoint and related hospitalizations through six months, both were significant. We go to the next slide, slide 22.
在兩項研究中,於LVAD植入時同步進行心肌內注射,注射內容為Revascor或對照。重要的是,兩項試驗、兩項隨機對照試驗皆顯示Revascor可降低重大出血事件的累積發生率、危及生命的腸胃道(GI)出血(亦為試驗主要療效與安全性終點)以及相關住院,在六個月內皆達顯著差異。我們看下一張投影片,第22張。
This provides you with some new data that we have not previously presented. This slide demonstrates the total number of major bleeding events resulting in hospitalizations over six months on the left-hand side and over 12 months compared to controls in the entire study LVAD II.
這裡提供一些我們先前未曾呈現的新資料。此投影片顯示在整個LVAD II研究中,左側為六個月內導致住院的重大出血事件總數,並與對照組比較;同時也呈現12個月的比較。
As you can see both on the left-hand side and the panel B on the right-hand side, Revascor reduced major bleeding events and hospitalizations by about fivefold, a very significant reduction throughout a 12-month period compared to MPC treatment compared to control treatment. Next slide, please. Now moreover, particularly in the ischemic group of patients, what you can see is that on the left-hand side, in controls, in red, the ischemic controls had approximately a three to fourfold increase in hospitalizations due to right heart failure.
如各位所見,無論是左側圖或右側的B圖,與對照治療相比,Revascor在12個月期間將重大出血事件與住院降低約五倍,為非常顯著的下降;相較於對照治療,亦優於MPC治療。請看下一張投影片。此外,特別是在缺血性病患族群中,各位可以看到左側對照組(紅色)中,缺血性對照病患因右心衰竭而住院的情形約增加三到四倍。
The non-ischemics had a very low incidence and risk of heart failure hospitalization. In contrast, on the right-hand side, by 12 months, you can see that the MPC treatment reduced the right heart failure hospitalization events in ischemic patients back to background levels, the same levels as I see in non-ischemic controls. And again, those reductions of hospitalization from right heart failure were significant. Next slide, please. This slide focuses on the risk of death from right heart failure in controls on the left, and in Revascor-treated patients on the right.
非缺血性病患的心衰竭住院發生率與風險非常低。相較之下,在右側圖中,到12個月時可見MPC治療將缺血性病患的右心衰竭住院事件降低回到背景水準,也就是與我在非缺血性對照病患所見的相同水準。同樣地,因右心衰竭導致的住院下降亦達顯著。請看下一張投影片。此投影片聚焦於對照組(左側)與Revascor治療病患(右側)因右心衰竭死亡的風險。
As you can see in Panel A on the left, amongst patient controls who have at least one hospitalization from right heart failure, the presence of -- sorry, amongst controls, the presence of right heart failure hospitalization, at least one right heart failure hospitalization in red was associated with a mortality risk and a hazard ratio of seven or more than seven compared to patients who did not have right heart failure.
如左側A圖所示,在對照病患中,至少曾因右心衰竭住院一次者(紅色)——抱歉——在對照組中,出現右心衰竭住院(至少一次,紅色)與死亡風險相關,其危險比達7或高於7,相較於未發生右心衰竭的病患。
So in controls, particularly early within the first four months after LVAD implantation, the presence of a right heart failure hospitalization was a very strong predictor of death. In contrast, what you can see on the right-hand side, amongst Revascor-treated patients, the risk of death, particularly in that early period four-month period is almost completely abolish.
因此在對照組中,特別是在LVAD植入後前四個月的早期階段,出現右心衰竭住院是死亡的非常強力預測因子。相反地,在右側可見於Revascor治療病患中,死亡風險,特別是在那段早期四個月期間,幾乎被完全消除。
And you can see that the overall survival over a 12-month period in Revascor-treated patient was the same, irrespective of whether they had a right heart failure hospitalization or not. So what this means is that Revascor not only reduces the incidence of hospitalization rates but protects these patients against death from right heart failure.
而且可以看到,在12個月期間,Revascor治療病患的整體存活率不受是否曾因右心衰竭住院影響,兩者相同。因此,這表示Revascor不僅降低住院發生率,也能保護這些病患免於因右心衰竭而死亡。
If you go to the next slide, please. So the summary of these new data, data that I haven't shown you here, but we have also observed is that Revascor reduces the inflammatory cytokines and through inflammation reduction protects the at-risk right ventricle in these patients, the same right ventricle that continues to fail despite the fact that there's an LVAD in the left ventricle.
請看下一張投影片。因此,這些新資料的總結——還有一些我在此未展示但我們也觀察到的資料——顯示Revascor可降低發炎性細胞激素,並透過降低發炎來保護這些病患中處於風險的右心室;即使左心室已有LVAD,這個右心室仍會持續衰竭。
The strengthened right ventricle reduces hospitalization rates in the intensive care unit due to right heart failure and improves survival. The strengthened right ventricle decreases the risk of portal hypertension and therefore, decreases GI bleeding events.
右心室功能增強可降低因右心衰竭而入住加護病房的住院率,並改善存活。右心室功能增強也會降低門脈高壓風險,因此降低腸胃道出血事件。
This leads us to think very carefully about how Revascor beyond its potential use in patients with left heart failure problems, also has the potential to be used to improve right heart failure function in patients not only with ischemic heart disease, but other causes of right heart failure, including primary pulmonary hypertension and chronic lung diseases.
這使我們非常審慎地思考:Revascor除了可能用於左心衰竭問題的病患之外,也有潛力用於改善右心衰竭功能;適用對象不僅是缺血性心臟病病患,也包括其他右心衰竭原因,例如原發性肺動脈高壓與慢性肺部疾病。
Next slide, please, slide 26. So let me give you an update on our CHF program, particularly our plans to file for approval. With these new data and our existing orphan drug designation for treating this group of high-risk patients with high mortality as well as FDA's stated preference for randomized controlled trials, Mesoblast is moving from filing for an accelerated approval to filing for a full approval.
請看下一張投影片,第26張。接著我更新我們的CHF計畫,特別是我們的申請核准規劃。基於這些新資料、我們既有的孤兒藥資格(用於治療這群高風險且高死亡率病患),以及FDA明確偏好隨機對照試驗的立場,Mesoblast正從申請加速核准轉為申請完整核准。
Unlike an accelerated approval, full approval does not require a confirmatory study. Aligned with FDA on items required for filing the BLA regarding CMC potency assays for product release and commercial manufacturing, we now have these activities well and truly underway, and we expect to file our BLA for full approval for this indication in the next quarter.
不同於加速核准,完整核准不需要確認性研究。在與FDA就BLA遞交所需事項(包括用於產品放行的CMC效價測定與商業化製造)達成一致後,我們已確實啟動並推進這些工作,並預期於下一季就此適應症遞交完整核准的BLA。
Let me summarize our highlights and our upcoming milestones. Ryoncil is the first and only FDA-approved MSC product. It delivered net revenues of USD49 million in the first half of FY26. As you heard, 49 centers have been onboarded, 64 centers account for 94% of the entire pediatric bone marrow transplant population, so well underway to achieve that in record time. We're initiating label expansion to adult acute GVHD, a market that is 3 times larger than the pediatric market.
讓我總結一下我們的亮點以及即將到來的里程碑。Ryoncil 是第一個也是唯一一個獲得 FDA 核准的 MSC 產品。在 FY26 上半年實現了 4,900 萬美元的淨營收。如各位所聽到的,已有 49 家中心完成導入;而 64 家中心涵蓋了整體小兒骨髓移植族群的 94%,因此我們正以創紀錄的速度穩步推進以達成該目標。我們正啟動適應症標籤擴展至成人急性 GVHD,該市場規模是小兒市場的 3 倍。
We are currently prioritizing our portfolio, which includes the potential to go into the inflammatory bowel disease, neurodegenerative diseases and respiratory conditions, and we will update the market as we focus on certain areas in priority over others. Our second-generation rexlemestrocel-L is enrolling the second trial in back pain with full enrollment expected to complete by the end of March or end of April.
我們目前正在優先排序產品組合,其中包括可能切入發炎性腸道疾病、神經退化性疾病以及呼吸系統疾病;隨著我們將某些領域的優先順序置於其他領域之上,我們也會向市場更新進展。我們第二代 rexlemestrocel-L 正在進行背痛的第二項試驗收案,預計在 3 月底或 4 月底完成全數收案。
BLA filing next quarter is in line for full approval for patients with right heart failure and end-stage heart failure with LVAD. And we're actively optimizing manufacturing logistics to support commercialization, both of the rexlemestrocel-L pipeline and obviously, to have further inventory for the projected growth in Ryoncil sales. With $130 million in cash on hand as of December 31, and the new credit line that you heard about, which still has the potential for $50 million available to draw down, we're in a very strong financial position.
我們預計於下季提交 BLA,並朝向針對右心衰竭與末期心衰竭(合併 LVAD)的患者取得完整核准。同時,我們正積極優化製造與物流,以支援商業化——包括 rexlemestrocel-L 產品線,當然也包括為預期的 Ryoncil 銷售成長準備更多庫存。截至 12 月 31 日我們持有 1.3 億美元現金,加上各位聽到的新信用額度(仍有最高 5,000 萬美元可動用),我們的財務狀況非常穩健。
And as you heard earlier, we are projecting full year fiscal 2026 Ryoncil net revenue to range between USD110 million and USD120 million. And I think I'll stop there. And hopefully, there are some questions that we can all address. Thank you.
另外,如先前所提,我們預估 2026 財政年度全年 Ryoncil 淨營收將介於 1.10 億至 1.20 億美元。我想我就先說到這裡。也希望接下來有一些問題我們可以一起回應。謝謝。
Paul Hughes - Head of Corporate Finance and Investor Relations
Paul Hughes - Head of Corporate Finance and Investor Relations
Operator, if you could please open the lines for questions. Thank you.
接線員,麻煩請開放提問線路。謝謝。
Operator
Operator
(Operator Instructions)
(接線員指示)
Edward Tenthoff, Piper Sandler
Edward Tenthoff,Piper Sandler
Edward Tenthoff - Analyst
Edward Tenthoff - Analyst
Congrats on all the great progress across the board. Could you just repeat the guidance you broke up a little bit for this coming year?
恭喜你們在各方面都取得很大的進展。你能否再重複一次你們對明年的指引?剛剛有點斷斷續續。
James O'Brien - Chief Financial Officer
James O'Brien - Chief Financial Officer
Yes. Yes. What we're projecting for the full fiscal year are net revenues ranging from $110 million to $120 million again, on a full year fiscal basis 2026 hitting June 2026.
好的。好的。我們對整個財政年度的預估是:淨營收介於 1.10 億至 1.20 億美元;同樣是以 2026 財政年度全年為基礎,財年結束於 2026 年 6 月。
Edward Tenthoff - Analyst
Edward Tenthoff - Analyst
I'll get back. I'll get back in the queue.
我先回去。我會回到隊列裡。
Operator
Operator
Olivia Brayer, Cantor Fitzgerald.
Olivia Brayer,Cantor Fitzgerald。
Olivia Brayer - Analyst
Olivia Brayer - Analyst
Hi guys, thank you for the questions. I have a few, if you don't mind. Maybe just first on Ryoncil in peds. You all mentioned potentially hitting 20% penetration of that pediatric population by the -- I think it was by the end of your fiscal year, if I heard that correctly.
嗨,各位,謝謝讓我提問。如果不介意的話,我有幾個問題。也許先從小兒適應症的 Ryoncil 談起。你們提到可能在——如果我沒聽錯的話——在你們財年結束前,達到小兒族群 20% 的滲透率。
So can you maybe just run through what those assumptions include to get to that 20%? And how high of penetration do you think you can realistically reach in this specifically peds population over time? And then I've got a couple more on your pipeline programs.
你們能否說明一下,要達到 20% 的假設包含哪些要素?另外,長期來看,在這個特定的小兒族群中,你們認為實際上能達到多高的滲透率?然後我還有幾個關於你們產品線計畫的問題。
Marcelo Santoro - Chief Commercial Officer
Marcelo Santoro - Chief Commercial Officer
Yes. So thank you. So let me start with the second one and then go to the first, right? So the second one, we assume a 40% peak share. And you have to understand, we believe it should be 100%.
好的。謝謝。那我先回答第二個問題,再回到第一個,好嗎?第二個部分,我們假設峰值市占率為 40%。但你必須理解,我們認為它應該是 100%。
This is a product that should be used by everyone. But let's be responsible and realistic, a 40% share is reasonable, right? So if you assume a range of patients, and obviously, that's dynamic of 375 patients, that's what the 20% is based on. It's 20% until the end of our fiscal year. That's what we aim on achieving at that point.
這是一個應該讓所有人都使用的產品。但我們要負責任、也要務實,40% 的市占率是合理的,對吧?因此,若你假設患者數的區間——當然這是動態的——以 375 名患者為基礎,這就是 20% 的計算依據。這個 20% 是到我們財年結束為止。那就是我們希望在那個時間點達成的目標。
Olivia Brayer - Analyst
Olivia Brayer - Analyst
And is that specifically for the fourth quarter of your fiscal year? Like if I'm kind of doing the math. Okay. That's helpful. And then for your Revascor BLA next quarter, how is the FDA viewing the ischemic versus non-ischemic phenotypes? And have they given any input on to or around potential labeling language around the ischemic etiology or inflammation biomarkers?
那這是特別指你們財年第四季的數字嗎?就我在做數學推算的話。好的。這很有幫助。另外,關於你們下季的 Revascor BLA,FDA 對缺血性與非缺血性表型是怎麼看的?他們是否對於可能的標籤文字(例如缺血病因或發炎生物標記)提供過任何意見?
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
Well, so I think it's important to note that in the 159-patient trial, we achieved the principal endpoint of -- in overall in the full patient population without having to go to any subgroups in terms of the cumulative incidence of major bleeding events over six months.
我想先強調一點:在 159 名患者的試驗中,我們在整體、完整的患者族群中達成了主要終點——不需要切到任何亞組——也就是在六個月內重大出血事件的累積發生率。
Also, we achieved a significant reduction in hospitalizations for major bleeding events across the entire patient population without having to go to subgroup. So our position is that we will be seeking a label for the entire patient population, especially given that the confirmatory study, LVAD I, also achieved the same endpoint across all patients. There's no question that the patients at greatest risk are those with ischemic etiology. And those patients have a higher level of inflammation, they have a higher risk for bleeding, right heart failure and death.
此外,我們也在整體患者族群中達成了重大出血事件住院率的顯著降低,同樣不需要切到亞組。因此,我們的立場是:我們將尋求涵蓋整體患者族群的標籤,特別是考量到確認性研究 LVAD I 也在所有患者中達成相同終點。毫無疑問,風險最高的患者是缺血性病因者。而這些患者的發炎程度更高,出血、右心衰竭與死亡的風險也更高。
And interestingly, we saw the very same sort of thing in the larger trial in Class II/III heart failure, where, again, we saw patients with ischemic heart disease as an etiology had high levels of inflammation, greater risk of 3-point MACE and greater treatment benefit.
有趣的是,我們在更大型的 II/III 級心衰竭試驗中也看到非常相同的情況:同樣地,以缺血性心臟病為病因的患者具有較高的發炎程度、較高的三點 MACE 風險,且治療獲益更大。
So we will be providing the FDA with the totality of the data that confirm the supportive trials, demonstration that ischemic patients are at greater risk and treatment with our cells is even more effective in that subgroup, but we've achieved the endpoint around the prespecified bleeding endpoint and hospitalization endpoint across the entire population. So that remains to be negotiated.
因此,我們會向 FDA 提供所有整體數據:包括支持性試驗的確認結果、證明缺血性患者風險更高,以及我們的細胞治療在該亞組中更有效;但我們也已在整體族群中達成預先指定的出血終點與住院終點。因此,這部分仍有待協商。
Olivia Brayer - Analyst
Olivia Brayer - Analyst
That's helpful. Understood. And then last question is just on the chronic back pain. Can you just clarify what data you're submitting to the FDA? Is it just a new analysis of the pre-existing data?
這很有幫助。了解。最後一個問題是關於慢性背痛。你能否澄清你們要提交給 FDA 的是哪些數據?是否只是對既有數據做新的分析?
And is your ongoing Phase III not actually going to be part of that submission package? Maybe just some clarity around that update because I do think that is a new disclosure.
那你們正在進行的第三期試驗其實不會納入那份提交資料包嗎?希望能釐清一下這次更新,因為我確實覺得這是新的揭露。
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
No, no, no. I didn't mean to say that we wouldn't be submitting the data from the new trial. The new trial, the second trial, which completes enrollment by over the next month to six weeks is the plan to complete enrollment. That trial becomes the primary data set and the previous trial becomes a supportive data set. That's certainly our intention.
不,不,不。我不是要說我們不會提交新試驗的數據。新試驗,也就是第二項試驗,計畫在接下來一個月到六週內完成收案。那項試驗將成為主要數據集,而先前的試驗將成為支持性數據集。這當然是我們的意圖。
We have spoken with the FDA about looking at the subgroup of patients who are opioid dependent and that's a discussion that is ongoing with the agency. But with respect to the primary endpoint in all comers of pain reduction, we will be using the two trials to present full data sets.
我們已與 FDA 討論過,是否要檢視對鴉片類藥物成癮(依賴)的患者亞組;這項討論仍在與主管機關進行中。但就主要終點——所有受試者的疼痛減輕——而言,我們將使用兩項試驗來呈現完整的數據集。
Olivia Brayer - Analyst
Olivia Brayer - Analyst
Okay. But that additional Phase III readout is coming in 2027, correct?
好的。但那項額外的第三期(Phase III)讀出會在 2027 年出來,對嗎?
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
That's correct.
沒錯。
Olivia Brayer - Analyst
Olivia Brayer - Analyst
So will you -- you're kicking off filing before actually having that data?
所以你們會——在實際拿到那些數據之前就啟動申報嗎?
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
No. The objective is to complete that trial, get the readout and move to a filing with those data in the primary file.
不會。目標是完成該試驗、取得讀出,並在主要申報資料中納入那些數據後再推進申報。
Operator
Operator
Madeleine Williams, Canaccord.
Madeleine Williams,Canaccord。
Madeleine Williams - Analyst
Madeleine Williams - Analyst
Hi, team. Thanks for taking my question. Just in regards -- just going back to the pediatric Ryoncil and just the FY26 guidance. Can you speak a little bit to sort of how you're seeing repeat utilization among centers or just how that kind of shakes out over the remaining of the year and sort of just trying to dig into more.
嗨,各位團隊。謝謝讓我提問。就——回到兒科 Ryoncil 以及 FY26 指引。你們能否多談一點,例如你們如何看待各中心的重複使用情況,或是今年剩餘時間這部分會如何發展?我想再深入了解一些。
Marcelo Santoro - Chief Commercial Officer
Marcelo Santoro - Chief Commercial Officer
Yes. No, we'd be happy to do that. Yes. So we see the continuous growth in the centers, continuous adoption, not only by more centers, but also repeated use by the current centers we already have, which shows that they are finding utility in the products and repeating the treatment in other children, right? So that's one component.
可以。不,我們很樂意說明。是的。我們看到中心數持續成長、採用持續增加,不僅是更多中心加入,也包括我們既有中心的重複使用,這顯示他們發現產品具有臨床效用,並在其他兒童身上重複進行治療,對吧?這是一個面向。
The second component, we're also seeing very big, very large centers coming on board, which will substantially increase our confidence in this guidance. And it's a reality that is happening every day.
第二個面向是,我們也看到非常大型、規模很大的中心加入,這將大幅提升我們對這項指引的信心。而且這是每天都在發生的現實情況。
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
And I would add to that, I think a major additional components moving forward is continued physician education. We've shown both in our previous Phase III trials and in the real-world data that the earlier this product is used, the greater the survival. it's unquestionable. And so a lot of the effort by the team will be to educate physicians. Physicians have their own practice habits.
我再補充一點,我認為未來一個主要的額外面向是持續的醫師教育。我們在先前的第三期試驗以及真實世界數據中都顯示,越早使用這個產品,存活率越高。這點無庸置疑。因此團隊很大一部分的努力會放在教育醫師上。醫師有各自的臨床習慣。
And they all believe that their particular way of doing things is standard. Nothing is standard in this disease, especially given that only Ryoncil is approved by FDA for treatment of children. So I think a major focus and an area of growth is to educate the majority to use the product as early as possible after steroid failure. Do you agree, Marcelo?
而且他們都相信自己那套做法就是標準。但在這個疾病上沒有什麼是標準,尤其考量到只有 Ryoncil 獲得 FDA 核准用於治療兒童。所以我認為一個主要重點與成長領域,是教育多數醫師在類固醇治療失敗後,盡可能早地使用本產品。Marcelo,你同意嗎?
Marcelo Santoro - Chief Commercial Officer
Marcelo Santoro - Chief Commercial Officer
For sure. And I would add one more, right? So as a father, unfortunately, my child had something like this horrible disease, I would like to know that this option is available. So it's our obligation to empower them to empower the caregivers, make sure that they understand that this product is available and it's the only FDA-approved product so that they can talk to their treatment teams and ask for this as a potential therapeutic option for their child.
當然。我再補充一點,對吧?身為父親,如果不幸我的孩子得了這種可怕的疾病,我會希望知道有這個選項可用。因此我們有責任去賦能他們、賦能照護者,確保他們了解這個產品可用,而且它是唯一獲 FDA 核准的產品,讓他們能與治療團隊討論,並為孩子提出把它作為潛在治療選項的需求。
Madeleine Williams - Analyst
Madeleine Williams - Analyst
Thank you, that's helpful. And just maybe one more from me, just in regards to revas score and the, full approval, filing for full approval rather than accelerated. I'm just interested, you've obviously discussed the additional data, but, I'm assuming there's sort of been some sort of constructive discussions with the FDA, and just sort of, if you can provide more color about what your confidence is in receiving that full approval.
謝謝,這很有幫助。我可能再問一個,關於 revas 分數以及「完全核准」——你們是以完全核准申報,而不是加速核准。我想了解的是,你們顯然已討論過額外數據,但我猜你們應該與 FDA 有過一些建設性的討論;如果可以的話,能否更具體說明你們對取得完全核准的信心來源?
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
Well, we've had multiple discussions with the agency. We understand what they wanted to see and the data that I've highlighted to you today, particularly as it relates to mortality is the number one area of focus. And the recent guidance by the agency to focus on randomized controlled trials rather than single-arm trials where major endpoints are being targeted like mortality give us the sort of confidence that particularly in an orphan disease indication where a single trial should be viewed as sufficient for approval, full approval.
我們已與主管機關進行多次討論。我們了解他們希望看到什麼,而我今天向你強調的數據,特別是與死亡率相關的部分,是第一優先的關注領域。此外,主管機關近期的指引是:在以死亡率等重大終點為目標時,應聚焦於隨機對照試驗,而非單臂試驗;這也讓我們更有信心,尤其在孤兒疾病適應症中,單一試驗應可被視為足以支持核准——完全核准。
Operator
Operator
(Operator Instructions)
(接線員指示)
Michael Okunewitch, Maxim Group.
Michael Okunewitch,Maxim Group。
Michael Okunewitch - Equity Analyst
Michael Okunewitch - Equity Analyst
Hey guys, thank you so much for taking my questions today and congrats on all the progress. I guess just to kick things off, there's obviously been a lot of changes at the FDA since you first launched the Phase III in chronic lower back pain. So I wanted to see if you've received confirmation from the current FDA administration that the 12-month pain-only endpoint is sufficient for approval?
各位好,非常感謝今天回答我的問題,也恭喜你們取得的所有進展。我想先從這裡開始:自你們在慢性下背痛啟動第三期試驗以來,FDA 顯然有很多變化。所以我想了解,你們是否已從現任 FDA 管理團隊那裡獲得確認:12 個月、僅以疼痛為終點(pain-only endpoint)就足以支持核准?
Silviu Itescu - Chief Executive Officer, Executive Director
Silviu Itescu - Chief Executive Officer, Executive Director
Yes, we have. Absolutely. That's exactly why we had the meeting recently to gain confirmation from the current administration that, that endpoint is an approvable endpoint, and that's exactly what we received. Moreover, the recent guidance from the FDA that a single well-conducted randomized controlled trial is sufficient for approvals in various indications also gives us great confidence that if we achieve that endpoint, this is an approvable trial and approval endpoint.
是的,我們有。完全是。這正是我們最近召開會議的原因:向現任管理團隊取得確認,該終點是可核准的終點,而我們確實得到了這樣的確認。此外,FDA 近期也有指引指出,在多種適應症中,一項設計良好且執行完善的隨機對照試驗即可支持核准;這也讓我們非常有信心:如果我們達成該終點,這就是一項可核准的試驗與核准終點。
Michael Okunewitch - Equity Analyst
Michael Okunewitch - Equity Analyst
And then just one more for me, and I'll hop back in the queue. I wanted to ask when it comes to the upcoming filing in the Class IV heart failure programs, are there any outstanding items that FDA has requested that you need to finalize before you can submit that next quarter?
我再問最後一個,然後我就回到排隊序列。關於下一季在第四級心衰竭(Class IV heart failure)項目的申報,FDA 是否有要求任何尚未完成、需要你們在提交前定案的事項?
Paul Hughes - Head of Corporate Finance and Investor Relations
Paul Hughes - Head of Corporate Finance and Investor Relations
Well, commercial manufacturing is always a very important component of this. And that is something that we are heavily engaged in. The product rexlemestrocel-L and its Phase III trials was all made at Lonza in the same facility where Ryoncil was made and which was approved for Ryoncil.
商業化製造一向是非常重要的一環。而這也是我們正積極投入的部分。產品 rexlemestrocel-L 及其第三期試驗用藥,都是在 Lonza 的同一座廠房製造;Ryoncil 也是在那裡製造,且該廠房已因 Ryoncil 而獲核准。
And we believe that the vast majority of the manufacturing process is quite similar to the Ryoncil process. So I think that will be an advantage in our filing, but that remains -- we need to get some more confirmation from the agency.
我們相信製造流程的絕大多數與 Ryoncil 的流程相當類似。因此我認為這會成為我們申報上的優勢,但這部分仍然——我們需要從主管機關取得更多確認。
Nonetheless, we expect that the long history of manufactured product for back pain trials, cardiac trials will hold us in good instead.
儘管如此,我們預期在背痛試驗、心臟試驗方面長期的產品製造歷史,將使我們處於有利位置。
Michael Okunewitch - Equity Analyst
Michael Okunewitch - Equity Analyst
All right, that's great to hear. Lots to look forward to up ahead. Thank you so much for taking my questions today.
好的,聽到這個很棒。接下來有很多值得期待的事情。非常感謝今天回答我的問題。
Operator
Operator
That brings us to the end of today's call. I'll hand back to Paul, please.
今天的電話會議到此結束。請把時間交還給 Paul。
Paul Hughes - Head of Corporate Finance and Investor Relations
Paul Hughes - Head of Corporate Finance and Investor Relations
Thank you. As you heard today, we're in a strong position with a number of significant milestones in this current second half through the period. We look forward to keeping you updated on the progress and the achievements. I'd like to thank everyone for their interest in Mesoblast and participation in the call today. Thank you and have a great day.
謝謝。如同各位今天所聽到的,我們在本期下半年至該期間內,將迎來多項重要里程碑,整體處於強勁的位置。我們期待持續向各位更新進展與成果。感謝大家對 Mesoblast 的關注並參與今天的電話會議。謝謝,祝各位有美好的一天。
Operator
Operator
That does conclude our conference for today. Thank you for participating. You may now disconnect.
今天的電話會議至此結束。感謝各位參與。您現在可以掛線。